Daxian Wu

Introduction Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome and is also considered a complex syndrome associated with high short-term mortality. Without timely and effective treatment, the mortality rate of ACLF can reach 50–90% (1). Worldwide, approximately 350 million people are infected with hepatitis B virus (2). ACLF caused by hepatitis B virus infection accounts for the majority of cases in Asia Pacific, especially in China (3).

HINT, a novel prognostic score based on hepatic encephalopathy, INR, neutrophil count, and thyroid‐stimulating hormone (TSH) using the deriving cohort (n = 426), was significantly higher in nonsurvivors than survivors (1.17 ± 2.38 vs −1.87 ± 1.26, P < 0.0001). The AUROC of HINT for 30‐day mortality was 0.889, which was significantly higher than that of the Child‐Pugh, MELD, CLIF‐SOFA, CLIF‐C ACLF, and COSSH‐ACLF scores (all P < 0.05).